Compared to advanced GC, EGC has a high 5-year survival rate, up to 99%. ĮGC has been defined as invasive gastric cancer confined to the mucosa or submucosa layer of the stomach, regardless of lymph node metastasis (LNM). It has been reported that the detection rate of EGC increased to 61% in Korea. One of the great achievements is the improvement of screening strategies for early GC (EGC) detection. Over the past several decades, these Eastern Asian countries have made great efforts to prolong the survival time and improve the quality of life of patients with GC. China accounted for 50% of the new cases. About 75% of cases appear in Asia, particularly in China, Korea, and Japan. Gastric cancer (GC) is the fifth most common cancer type and the third leading cause of cancer-related mortality worldwide. Pylorus-preserving gastrectomy for patients with middle-third EGC remains controversial due to the high metastasis rate of the No.
Patients with EGC conforming to expanded indications have a relatively high risk of LNM and may not be suitable for endoscopic submucosal dissection. The independent risk factors for LNM were tumors measuring > 30 mm, poorly differentiated tumors, and lymphovascular invasion (all P 20 mm and LNM were independent predictive factors for poor survival outcome in all patients. For those with middle-third tumor, the metastasis rate of the No. Skip LNM was observed in 3.67% (13/354) of patients. The rates of LNM in absolute indication of endoscopic resection and expanded indication were 3.27% (2/61) and 28.55% (4/14), respectively. The incidence of LNM in all patients was 18.36% (65/354). Their clinicopathological features, pathological reports, and prognostic data were collected and analyzed. MethodsĪ total of 354 patients with carcinoma in situ ( n = 42), EGC ( n = 312) who underwent radical gastrectomy were enrolled.
This study aimed to evaluate the pattern and clinical significance of LNM in EGC. Lymph node metastasis (LNM) status is an important prognostic factor that strongly influences the treatment decision of early gastric cancer (EGC).